Early Access

Early Access

ADC Therapeutics is committed to confronting cancer with the full potential of its science, bringing unique, targeted therapies and hope to patients and their families. Medical Affairs delivers scientific data and knowledge of the highest scientific and ethical standards to the healthcare community and the patients we serve.

ADC Therapeutics will consider and evaluate requests for patient access to loncastuximab tesirine (lonca) in countries outside of the United States, excluding greater China and Singapore.

Treating physicians can submit a request and ADC Therapeutics will acknowledge the inquiry within 3 business days.

Access to lonca is subject to the rules, regulations, and any applicable approval(s) in the individual countries. Questions should be directed to eap@adctherapeutics.com, or our partner, WEP Clinical, lonca@wepclinical.com.